ADVANCED MEDICAL SOLUTIONS GROUP PLC

Share Issue/Capital Change • May 15, 2025

National Storage Mechanism | Additional information

RNS Number : 9167I

Advanced Medical Solutions Grp PLC

15 May 2025

	15 May 2025

Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

Director/PDMR Shareholding

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces the following Director share transactions.

The Company was notified on 12 May 2025 that on the same day, Individual Savings Accounts ("ISA's") held in the name of Susan Searle, Non-Executive Director, purchased 5,000 ordinary shares of 5p each ("Ordinary Shares") at a price of 194.83p per Ordinary Share and ISA's held by Fraser Searle, husband and a PCA of Susan Searle, purchased 5,000 Ordinary Shares at a price of 194.83p per Ordinary Share. Following these transactions, Susan Searle and persons closely associated hold 0.005% of the issued share capital.

As part of the Share Incentive Plan ("SIP") and Employee Share Purchase Plan ("ESPP), Executive Directors and employees can sacrifice part of their annual bonus and/or salary into the SIP and ESPP, which for every share purchased on behalf of the employee they receive matching shares which are deferred for a minimum of three years. Chris Meredith (CEO) and Eddie Johnson (CFO) have elected to sell certain existing shares to use the proceeds to re-invest in the SIP and ESPP.

The Company was notified on 12 May 2025 that following his decision to participate Chris Meredith, who is a Director and PDMR, executed the exercise of 64,000 nil-cost options from the existing Long Term Incentive Plan ("LTIP") and subsequently sold 64,000 Ordinary Shares of 5p each on 12 May 2025 at a share price of 194.61 p per Ordinary Share. The proceeds from the sale of the shares were used to purchase shares in the SIP and ESPP, as detailed below.

The Company was further notified on 12 May 2025 that following his decision to participate Eddie Johnson, who is a Director and PDMR, executed the exercise of 28,126 nil-cost options from the existing Long Term Incentive Plan ("LTIP") and subsequently sold 28,126 Ordinary Shares of 5p each on 12 May 2025 at a share price of 196.4 p per Ordinary Share. The Company was further notified on 13 May 2025 that Eddie Johnson had exercised 16,402 nil-cost Matching Shares from the ESPP and subsequently sold 16,402 Ordinary Shares of 5p each on 13 May 2025 at a share price of 194.62 p per Ordinary Share. The proceeds from the sale of the shares were used to purchase shares in the SIP and ESPP, as detailed below.

The Trust which manages the SIP and ESPP on behalf of the employees of AMS has purchased Ordinary Shares of 5p each ("Ordinary Shares") on 12 May 2025, at a share price of 195.04p on behalf of Chris Meredith (923 Ordinary Shares into the SIP, 32,168 Ordinary Shares into the ESPP) and Eddie Johnson (923 Ordinary Shares into the SIP, 20,669 Ordinary Shares into the ESPP), who are both Directors/PDMRs, as part of the SIP and, under the terms of the SIP and ESPP, these shares will be held in trust on their behalf. The Company was notified of the completion of these purchases on 15 May 2025.

In addition Chris Meredith and Eddie Johnson further exercised outstanding nil-cost LTIPs and nil-cost ESPP Matching Shares in order to transfer them into their own names, selling a proportion to cover tax and National Insurance.

The Company was notified on 12 May 2025 that Chris Meredith exercised 307,210 nil-cost LTIPs and 114,518 nil-cost ESPP Matching Shares and subsequently sold 211,521 Ordinary Shares at a share price of 193.80 p per Ordinary Share on 12 May 2025 , retaining 210,207 Ordinary Shares in his own name.

The Company was notified on 13 May 2025 that Eddie Johnson exercised 130,776 nil-cost LTIPs, 86,184 nil-cost ESPP Matching Shares and 12,737 Deferred Bonus Shares and subsequently sold 115,206 Ordinary Shares at a share price of 194.62 p per Ordinary Shares on 13 May 2025, retaining 114,491 Ordinary Shares in his own name.

The number of shares held by Chris Meredith and Eddie Johnson and their PCAs will increase their beneficial interest in the Company from the level prior to these transactions and the beneficial ownership of Chris Meredith and Eddie Johnson are as follows:

Director/PDMR	Date purchased/ transferred	Shares purchased (through SIP and ESPP)	Shares retained from exercises	Resultant holding	% of issued share capital
Chris Meredith Chief Executive Officer	12 May 2025	33,091	210,207	2,045,694	0.94%
Eddie Johnson Chief Financial Officer	12 May 2025 and 13 May 2025	21,592	114,491	313,638	0.14%

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

1. Susan Searle

2. Fraser Searle

2.

Reason for the notification

a)

Position/status:

1. Non-Executive Director

2. PCA to a Non-Executive Director

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Purchase of Ordinary Shares into ISAs for a Non-Executive Director (Susan Searle)

·        Purchase of Ordinary Shares into ISAs for a PCA of a Non-Executive Director (Fraser Searle)

c)

Price(s) and volume(s):

Price(s)	Volume(s)
Purchase of Ordinary Shares at 194.83p per share for a Non-Executive Director (Susan Searle)	5,000
Purchase of Ordinary Shares at 194.83p per share for a PCA of a Non-Executive Director (Fraser Searle)	5,000

d)

Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transactions: 12/05/2025

f)

Place of the transaction: London Stock Exchange (XLON)

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Chris Meredith

2.

Reason for the notification

a)

Position/status: Chief Executive Officer

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Exercise of nil-cost LTIPs

·        Exercise of nil-cost ESPP Matching Shares

·        Sale of O rdinary Shares of 5p from the nil-cost LTIP and nil-cost ESPP

·        Purchase of Ordinary Shares as part of the SIP and ESPP on 12 May 2025

c)

Price(s) and volume(s):

Price(s)	Volume(s)
Exercise of nil-cost LTIPs	64,000
Sale of shares from LTIP at 194.61p per share	64,000
Exercise of nil-cost LTIPs and nil- cost ESPP Matching Shares	421,728
Sale of shares from LTIP and ESPP at 193.80p per share	211,521
Purchase by SIP and ESPP at 195.04p per share	33,091

d)

Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transactions: 12/05/2025

f)

Place of the transaction: London Stock Exchange (XLON)

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Eddie Johnson

2.

Reason for the notification

a)

Position/status: Chief Financial Officer

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Exercise of LTIPs

·        Exercise of ESPP Matching Shares

·        Exercise of Deferred Bonus Share

·        Sale of O rdinary Shares of 5p from the LTIP and ESPP

·        Purchase of Ordinary Shares as part of the SIP and ESPP on 12 May 2025

c)

Price(s) and volume(s):

Price(s)	Volume(s)
Exercise of nil-cost LTIPs and nil-cost ESPP Matching Shares	44,528
Sale of shares from LTIP at 196.40p per share	28,126
Sale of shares from ESPP at 194.62p per share	16,402
Exercise of nil-cost LTIPs, nil- cost ESPP Matching Shares and Deferred Bonus Shares	229,697
Sale of shares from LTIP, ESPP and Deferred Bonus at 194.62p per share	115,206
Purchase by SIP and ESPP at 195.04p per share	21,592

d)

Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transactions: 12/05/2025 and 13/05/2025

f)

Place of the transaction: London Stock Exchange (XLON)

- Ends -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations
ICR Consilium	Tel: +44 (0) 20 3709 5700
Mary-Jane Elliott / Lucy Featherstone	[email protected]
Investec Bank PLC (NOMAD & Broker)	Tel: +44 (0) 20 7597 5970
Gary Clarence / David Anderson
HSBC Bank PLC (Broker)	Tel: 44 (0) 20 7991 8888
Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,500 employees. For more information, please see www.admedsol.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBRGDUXDBDGUU